Market Overview

Loncar Cancer Immunotherapy Index Announces Merger Replacements

Share:

Gilead and NewLink Added to the Only Index that Tracks Cancer
Immunotherapy

Loncar Investments, LLC today announced two new additions to the Loncar
Cancer Immunotherapy Index
, a group of the top 30 companies
developing cancer immunotherapy treatments and discovering new ways to
use the body's immune system to fight cancer.

The index committee has added Gilead Sciences (NASDAQ:GILD) and NewLink
Genetics (NASDAQ:NLNK). They replace Amgen (NASDAQ:AMGN) and Kite
Pharma (NASDAQ:KITE), respectively.

These changes come after Gilead Sciences' successful $11.9 billion
acquisition of Kite Pharma.

Following the completion of this transaction, Gilead has emerged as a
new leader in the CAR-T cellular immunotherapy field. Furthermore,
NewLink is at the forefront of researching the role of the indoleamine
2,3-dioxygenase (IDO) pathway in cancer, an immune modulator involved in
tumor escape.

"We are grateful for all that Kite has accomplished for patients who
will benefit from CAR-T and look forward to watching Gilead build on
this success," said Brad Loncar, Chairman of the index committee. "CAR-T
is the fifth type of modern day immunotherapy that has been approved by
FDA. It joins checkpoint inhibitors, oncolytic viruses, bispecific
antibodies and cancer vaccines as approved approaches. We are very
pleased to see this momentum in the field."

The above changes were made after a special meeting of the index's
committee and according to its rules. The next regularly scheduled
semi-annual rebalance and reconstitution of the index will occur on
December 19, 2017.

Loncar Investments is an official partner of the Cancer
Research Institute
, the world's longest running nonprofit
organization dedicated exclusively to harnessing the immune system's
power to conquer all cancers. To learn about how to give to CRI, please
visit here.

Why immunotherapy: Cancer immunotherapy has become an important
sector in the biotechnology space and is changing the way many cancers
are treated. While traditional medicines like chemotherapies often give
cancer a broad punch, the benefit of using immunotherapy is derived from
the immune system's dynamic nature and the way it can more precisely be
tailored to fight a patient's disease.

About the index: The Loncar Cancer Immunotherapy Index is an
equal-weighted index of 30 top immunotherapy companies rebalanced and
reconstituted on a semi-annual basis. Price and return data are
independently calculated on a daily basis by Indxx, LLC. This is a
sector index similar to Technology sector indices (Internet, Cyber
Security, Robotics, etc.). Sector indices allow investors to track
interest areas more precisely than broad indices. Additional information
can be found at the index's dedicated website, www.LoncarIndex.com.

Index provider: Loncar Investments, LLC is committed to making
the biotechnology space more approachable to a wider range of investors.
The company is principally owned by biotech investor and analyst Brad
Loncar. Mr. Loncar manages a biotech-focused family portfolio from his
Lenexa, Kan. office. He can be followed on Twitter at @bradloncar
and his commentary is available at www.loncarblog.com.

View Comments and Join the Discussion!